Biogen, Sage prep 2022 filing for depression drug zuranoloneThe renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to Share XBiogen, Sage prep 2022 filing for depression drug zuranolonehttps://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/
Limbix’ digital therapeutic cuts depression symptoms in young peopleLimbix is moving ahead with plans to file for FDA approval of its SparkRx digital therapeutic (DTx) for Share XLimbix’ digital therapeutic cuts depression symptoms in young peoplehttps://pharmaphorum.com/news/limbix-digital-therapeutic-cuts-depression-symptoms-in-young-people/
Electrical implant treats severe depression in US patientResearchers in the US have successfully treated a patient with severe depression via the use of an implant Share XElectrical implant treats severe depression in US patienthttps://pharmaphorum.com/news/electrical-implant-treats-severe-depression-in-us-patient/
Axsome faces delay for depression drug, hitting shares hardThe FDA was supposed to be delivering its verdict on Axsome Therapeutics’ depression therapy AXS-05 in less than Share XAxsome faces delay for depression drug, hitting shares hardhttps://pharmaphorum.com/news/axsome-faces-delay-for-depression-drug-hitting-shares-hard/
Happify launches Ensemble DTx for depression, anxiety in USHappify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment Share XHappify launches Ensemble DTx for depression, anxiety in UShttps://pharmaphorum.com/news/happify-launches-ensemble-dtx-for-depression-anxiety-in-us/
Digital mental health specialist Woebot raises $90mInvestments in digital health firms are running high at the moment, and a $90 million round for four-year-old Share XDigital mental health specialist Woebot raises $90mhttps://pharmaphorum.com/news/digital-mental-health-specialist-woebot-raises-90m/
Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Study finds “alarming” hike in antidepressant costs during COVID-19Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in Share XStudy finds “alarming” hike in antidepressant costs during COVID-19https://pharmaphorum.com/news/study-finds-alarming-hike-in-antidepressant-costs-during-covid-19/
Small Pharma stock market launch funds DMT-based depression drug trialUK-based Small Pharma has launched on the Toronto’s TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) Share XSmall Pharma stock market launch funds DMT-based depression drug trialhttps://pharmaphorum.com/news/small-pharma-launches-on/
